After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffersKey Takeaways:YZY Biopharma has filed for a Hong…
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
